A case of pulmonary adenocarcinoma with overexpression of multidrug resistance-associated protein and p53 aberration

Anticancer Research

Volumn 20, Issue 3 B, 2000, Pages 1921-1925

  Nakamura, Masato ^a   Abe, Yoshiyuki ^a,b   Katoh, Yuko ^a   Oshika, Yoshiro ^a   Hatanaka, Hiroyuki ^a   Tsuchida, Takashi ^a   Yamazaki, Hitoshi ^a   Kijima, Hiroshi ^a   Inoue, Hiroshi ^a   Ueyama, Yoshito ^a  

^a TOKAI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b Kanagawa National Hospital   (Japan)

Author keywords

Chemotherapy; Multidrug resistance associated protein; p53; Pulmonary adenocarcinoma

Indexed keywords

CARBOPLATIN; ETOPOSIDE; MULTIDRUG RESISTANCE PROTEIN; PROTEIN P53;

AGED; ARTICLE; CANCER RECURRENCE; CASE REPORT; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LUNG ADENOCARCINOMA; LUNG METASTASIS; LYMPH NODE METASTASIS; MEDIASTINUM LYMPH NODE; PRIORITY JOURNAL; PROTEIN EXPRESSION; RESPIRATORY FAILURE;

ADENOCARCINOMA, PAPILLARY; AGED; CARCINOMA, NON-SMALL-CELL LUNG; DNA MUTATIONAL ANALYSIS; DNA, NEOPLASM; DRUG RESISTANCE, MULTIPLE; DRUG RESISTANCE, NEOPLASM; FATAL OUTCOME; FEMALE; GENES, MDR; GENES, P53; HUMANS; LUNG NEOPLASMS; LYMPHATIC METASTASIS; NEOPLASM RECURRENCE, LOCAL; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; TUMOR CELLS, CULTURED;

EID: 0033877280     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (21)

1. Yang CH, Cheng AL, Yeh KH, Yu CJ, Lin JF and Yang PC: High dose tamoxifen plus cisplatin and etoposide in the treatment of patients with advanced, inoperable nonsmall cell lung carcinoma. Cancer 86: 415-420, 1999.
2. Soria J-H, Chevalier TL, Pechoux CL and Arriagada R: Multimodality therapy in locally advancednon-smallcell lung cancer (NSCLC stage HIB). Lung Tumors (Brambilla C and Brambilla E, edts), New York Marcel Dekker INC. 1999, pp553-565.
3. Richards II F, Perry DJ, Goutsou M, Modeas C, Muchmore E, Rege V, Chahinian AP, Hirsh V, Poiesz B and Green MR: Chemotherapy with 5-fluorouracil (5-FU) and cisplatin or 5-FU, cisplatin, andvinblastine for advancednon-small cell lung cancer. Cancer 67: 2974-2979, 1991.
4. Iacobelli S, Irtelli L, Sacco R, Martino M, Miscitelli E, Basilico L Scognamiglio M, Natoli C, Fusco O, Tinari N and Beltrami V: Aphase II study of neoajuvant chemotherapy with cisplatin epirubicin and VP-16 for stage III unresectable non-small cell lung cancer. Anticancer Res 18: 2081-2084, 1998.
5. Fojo AT, Whang-Peng J, Gottesman MM and Pastan I: Amplification of DNA sequences in human multidrug-resistant KB carcinoma cells. Proc Natl Acad Sci USA 82: 7661-7665, 1985.
6. Gros P, Neriah YB, Croop JM and Housman DE: Isolation and expression of a complementary DNA that confers multidrug resistance. Nature 323: 728-731, 1986.
7. Giaccone G, Gazdar AF, Beck H, Zunino F and Capranico G: Multidrug sensitivity phenotype of human lung cancer cells associated with Topoisomerase II expression. Cancer Res 52; 1666-1674, 1992.
8. Abe Y, Nakamura M, Ota E, Ozeki Y, Tamai S, Inoue H, Ueyama Y, Ogata T and Tamaoki N: Expression of the multidrug resistance gene (MDR1 ) in non small cell lung cancer. Jpn J Cancer Res 85: 536-541, 1994.
9. Cole SPC, Bhardwaj G, Gerlach JH, Mackie JE, Grant CE, Almquist KC, Stewart AJ, Kurz EU, Duncan AMV and Deely RG: Overexpression of a transporter gene in a multidrug-resistant human lungcancer cell line. Science 258: 1650-4, 1992.
10. Grant CE, valdimarsson G, Hipfner DR, Almquist KC, Cole SPC and Deeley RG: Overexpression of Multidrug Resistance-associated Protein (MRP) increases resistance to natural product drugs. Cancer Res54: 357-361, 1994.
11. Ota E, Abe Y, Oshika Y, Ozcki Y, Iwasaki M, Inoue H, Yamazaki H, Ueyama Y, Takagi K, Ogata T, Tamaoki N and Nakamura M: Expression of the multidrug resistance-associated protein (MRP) gene in non-small-cell lung cancer. Br J Cancer 72: 550-554, 1995.
12. Oshika Y, Nakamura M, Tokunaga T, Fukushima Y, Abe Y, Ozeki Y, Yamazaki H, Tamaoki N and Ueyama Y: Multidrug resistance-associated protein and mutant p53 protein expression in non-small cell lung cancer. Mod Pahol 11: 1059-1063, 1998.
13. Toth K, Vaughan MN, Slocum HK, Arredondo MA, Takata H, Baker RM and Rustum YM: New immunohistochemical "Sandwich" staining method for MDR1 P-glycoprotein detection with JSB-1 monoclonal antibody in formalin-fixed, paraffin-embedded human tissues. Am J Pathol 144: 227-236, 1994.
14. Casey G, Lopez ME, Ramos JC, Plummer SJ, Arboleda MJ, Shaughnessy M, Karlan B and Slamon DJ: DNA sequence analysis of exon 2 through 11 and immunohistochemical staining are required to detect all known p53 alterations in human malignancies. Oncogene 13: 1971-1981, 1996.
15. Chin KV, Ueda K, Pastan and Gottesman MM: Modulation of activity of the promoter of the human MDR1 gene by ras and p53. science 255: 459-462, 1992.
16. Hirose M and Kuroda Y: p53 may mediate the MDR1 expression the WT1 gene in human vincristine-resistant leukemia lymphoma cell lines. Cancer Lett 17: 165-171, 1998.
17. Wang Q and Beck WT: Transcriptional supression of multidrug resistance-associated protein (MRP) gene expression by wild-type p53. Cancer Res 58: 5762-5769, 1998.
18. Mizoguchi T, Yamada K, Furukawa T, Hidaka K, Hisatsugu T, Shimizu H, Tsuruo T, Sumizawa T and Akiyama S: Expression of the MDR1 gene in human gastric and colorectal carcinoma. J Natl Cancer Inst 82: 1679-1683, 1990.
19. Suto R, Abe Y, Lee YH, Ueyama Y, Yamazaki H, Kijima H, Hiraoka N, Fukuda H, Tamaoki N and Nakamura M. A case of malignant schwannoma with overexpression ofmultidrug resistance gene (MDR1) after chemotherapy. Antican Res 17: 2273-2278, 1997.
20. Twentyman PRA and Versantvoort CHM: Experimental modulation of MRP (multidrug resistance-associated protein)-mediated resistance. Eur J Cancer 32A: 1002-1009, 1996.
21. Stewart AJ, Canitrot Y, Barcchini E, Dean NM, Deely RG and Cole SPC: Reduction of expression of the multidrug resistance protein (MRP) in human tumor cells by antisence phosphorothioate oligonucleotides. Biochem Pharmacol 51: 461-469, 1996.